Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab + erlotinib versus placebo + erlotinib in Met-positive previously treated advanced NSCLC
NL-OMON39593Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing erlotinib + Onartuzumab with erlotinib + placebo (2 arms). Primary endpoint: Overall survival. Started Oct 2012; status: active, not recruiting.
02
Drugs
onartuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON39593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39593.